-+ 0.00%
-+ 0.00%
-+ 0.00%

Changchun Hi-Tech announced that the holding subsidiary Changchun Jinsai Pharmaceutical Co., Ltd.'s application for the marketing of quintuximab injections was accepted by the State Drug Administration. The drug is a recombinant anti-VEGFR 2-person mouse chimeric monoclonal antibody. It is indicated for use in combination with paclitaxel for patients with advanced gastric or gastroesophageal conjunctive adenocarcinoma who have failed previous first-line treatment. Quintuximab injections can specifically bind VEGFR2 to block the VEGF-VEGFR2 signaling pathway and inhibit tumor angiogenesis, thereby inhibiting tumor cell growth.

Zhitongcaijing·07/21/2026 09:09:11
Listen to the news
Changchun Hi-Tech announced that the holding subsidiary Changchun Jinsai Pharmaceutical Co., Ltd.'s application for the marketing of quintuximab injections was accepted by the State Drug Administration. The drug is a recombinant anti-VEGFR 2-person mouse chimeric monoclonal antibody. It is indicated for use in combination with paclitaxel for patients with advanced gastric or gastroesophageal conjunctive adenocarcinoma who have failed previous first-line treatment. Quintuximab injections can specifically bind VEGFR2 to block the VEGF-VEGFR2 signaling pathway and inhibit tumor angiogenesis, thereby inhibiting tumor cell growth.